{
    "ticker": "PSIL",
    "name": "PsiQ, Inc.",
    "description": "PsiQ, Inc. is an innovative biotechnology company focused on developing advanced therapeutics that leverage the power of psychedelics and neurobiology to treat a range of mental health disorders. Founded in 2019, PsiQ aims to revolutionize mental health treatment by exploring the therapeutic potential of psychedelics, including psilocybin and MDMA, through rigorous scientific research and clinical trials. The company\u2019s mission is to enhance the understanding of the human brain and develop safer, more effective treatment options for conditions such as depression, anxiety, PTSD, and substance abuse disorders. PsiQ collaborates with leading research institutions and employs state-of-the-art methodologies to ensure the efficacy and safety of its products. With a commitment to ethical practices and patient-centered care, PsiQ is pioneering a new era of mental health treatment, advocating for the destigmatization of psychedelic therapy and promoting comprehensive mental well-being. As the demand for innovative mental health solutions grows, PsiQ is positioned at the forefront of this emerging industry, driven by a vision to create a profound impact on global health.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "San Francisco, California, USA",
    "founded": "2019",
    "website": "https://www.psiq.com",
    "ceo": "Dr. Emily Carter",
    "social_media": {
        "twitter": "https://twitter.com/PsiQ_Inc",
        "linkedin": "https://www.linkedin.com/company/psiq-inc/"
    },
    "investor_relations": "https://ir.psiq.com",
    "key_executives": [
        {
            "name": "Dr. Emily Carter",
            "position": "CEO"
        },
        {
            "name": "Robert Johnson",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Psychedelic Therapies",
            "products": [
                "Psilocybin Capsules",
                "MDMA-Assisted Therapy"
            ]
        },
        {
            "category": "Research Services",
            "products": [
                "Clinical Trials",
                "Neurobiological Studies"
            ]
        }
    ],
    "seo": {
        "meta_title": "PsiQ, Inc. | Innovative Psychedelic Therapies for Mental Health",
        "meta_description": "Explore PsiQ, Inc., a biotechnology company dedicated to developing psychedelic-based therapies for mental health disorders. Learn about our mission, research, and innovative products.",
        "keywords": [
            "PsiQ",
            "Psychedelics",
            "Mental Health",
            "Psilocybin",
            "MDMA",
            "Biotechnology",
            "Therapeutics"
        ]
    },
    "faq": [
        {
            "question": "What does PsiQ focus on?",
            "answer": "PsiQ focuses on developing psychedelic-based therapies for mental health disorders."
        },
        {
            "question": "Who is the CEO of PsiQ?",
            "answer": "Dr. Emily Carter is the CEO of PsiQ, Inc."
        },
        {
            "question": "Where is PsiQ headquartered?",
            "answer": "PsiQ is headquartered in San Francisco, California, USA."
        },
        {
            "question": "What are PsiQ's main products?",
            "answer": "PsiQ's main products include psilocybin capsules and MDMA-assisted therapy."
        },
        {
            "question": "When was PsiQ founded?",
            "answer": "PsiQ was founded in 2019."
        }
    ],
    "competitors": [
        "ATXI",
        "CMPS",
        "SNDL"
    ],
    "related_stocks": [
        "AAPL",
        "TSLA",
        "AMZN",
        "NVDA"
    ]
}